193 related articles for article (PubMed ID: 24068485)
21. The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate.
Soukup T; Dosedel M; Nekvindova J; Antonin Kubena A; Tacheci I; Duintjer Tebbens J; Vlcek J; Bradna P; Barvik I; Pavek P
Pharmacogenet Genomics; 2017 Feb; 27(2):43-50. PubMed ID: 27846189
[TBL] [Abstract][Full Text] [Related]
22. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
[TBL] [Abstract][Full Text] [Related]
23. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.
van Ede AE; Laan RF; Blom HJ; Boers GH; Haagsma CJ; Thomas CM; De Boo TM; van de Putte LB
Rheumatology (Oxford); 2002 Jun; 41(6):658-65. PubMed ID: 12048292
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate.
Kim SK; Jun JB; El-Sohemy A; Bae SC
J Rheumatol; 2006 Jul; 33(7):1266-74. PubMed ID: 16758511
[TBL] [Abstract][Full Text] [Related]
25. The pharmacogenetics of methotrexate.
Hider SL; Bruce IN; Thomson W
Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
[TBL] [Abstract][Full Text] [Related]
26. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.
van Ede AE; Laan RF; Blom HJ; Huizinga TW; Haagsma CJ; Giesendorf BA; de Boo TM; van de Putte LB
Arthritis Rheum; 2001 Nov; 44(11):2525-30. PubMed ID: 11710708
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review.
Kougkas N; Dara A; Pagkopoulou E; Dimitriadou A; Papadimitriou E; Avdelidou E; Garyfallos A; Dimitroulas T
Rheumatol Int; 2022 Oct; 42(10):1849-1854. PubMed ID: 35849191
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
Wessels JA; de Vries-Bouwstra JK; Heijmans BT; Slagboom PE; Goekoop-Ruiterman YP; Allaart CF; Kerstens PJ; van Zeben D; Breedveld FC; Dijkmans BA; Huizinga TW; Guchelaar HJ
Arthritis Rheum; 2006 Apr; 54(4):1087-95. PubMed ID: 16572443
[TBL] [Abstract][Full Text] [Related]
29. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.
Kurzawski M; Pawlik A; Safranow K; Herczynska M; Drozdzik M
Pharmacogenomics; 2007 Nov; 8(11):1551-9. PubMed ID: 18034620
[TBL] [Abstract][Full Text] [Related]
30. Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis.
Calvo-Romero JM
Ann Pharmacother; 2001 Dec; 35(12):1575-7. PubMed ID: 11793624
[TBL] [Abstract][Full Text] [Related]
31. Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis.
Worthley SG; McNeil JD
J Rheumatol; 1995 Feb; 22(2):335-7. PubMed ID: 7738959
[TBL] [Abstract][Full Text] [Related]
32. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
Lee YH; Song GG
Clin Drug Investig; 2010; 30(2):101-8. PubMed ID: 20067328
[TBL] [Abstract][Full Text] [Related]
33. Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients?
Ghodke Y; Chopra A; Joshi K; Patwardhan B
Clin Rheumatol; 2008 Jun; 27(6):787-9. PubMed ID: 18274813
[TBL] [Abstract][Full Text] [Related]
34. [Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience].
Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
Reumatismo; 2009; 61(2):98-106. PubMed ID: 19633796
[TBL] [Abstract][Full Text] [Related]
35.
Sundbaum JK; Baecklund E; Eriksson N; Hallberg P; Kohnke H; Wadelius M
Pharmacogenomics; 2020 Apr; 21(5):337-346. PubMed ID: 32024416
[No Abstract] [Full Text] [Related]
36. Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study.
Dhaon P; Das SK; Srivastava R; Agarwal G; Asthana A
Int J Rheum Dis; 2018 May; 21(5):1010-1017. PubMed ID: 27455886
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
Dervieux T
J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
[No Abstract] [Full Text] [Related]
38. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
39. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
Nesa L; Gobbi C; Alba P; Exeni I; Babini A; Albiero E
Rev Fac Cien Med Univ Nac Cordoba; 2007; 64(4):109-14. PubMed ID: 19928400
[TBL] [Abstract][Full Text] [Related]
40. Association of
Wang S; Zuo S; Liu Z; Ji X; Yao Z; Wang X
J Int Med Res; 2020 Feb; 48(2):300060519879588. PubMed ID: 31617429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
